<DOC>
	<DOCNO>NCT01242813</DOCNO>
	<brief_summary>This trial ass safety efficacy ACZ885 patient active recurrent chronic TNF-receptor associate periodic syndrome ( TRAPS ) .</brief_summary>
	<brief_title>Efficacy Safety Study ACZ885 Patients With Active Recurrent Chronic TNF-receptor Associated Periodic Syndrome ( TRAPS ) .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Hereditary Autoinflammatory Diseases</mesh_term>
	<criteria>1 . Patient 's write informed consent &gt; or= 18 year age assessment perform . Parent legal guardian 's write informed consent child 's assent , appropriate , required assessment perform patient &lt; 18 year age . 2 . Male female patient least 4 year age time screen visit . 3 . Patients clinical diagnosis TRAPS mutation TNFRSF1A gene . Patients low penetrance mutation , R92Q P46L , include mutual agreement investigator Novartis . 4 . Patients diagnosis recurrent TRAPS must experience 6 episodes/year prior receive effective biologic therapy duration episode last least 8 day . For patient receive biologic therapy , criterion applies prior receive biologic therapy . 5 . Patients treat anakinra must demonstrate partial complete clinical response associate decrease inflammation marker ( CRP SAA ) . 6 . Active TRAPS evidence clinical sign symptom active TRAPS ( Physician 's Global Assessment &gt; or= 2 ) elevate CRP &gt; 10mg/L ( Normal CRP range &lt; or= 10 mg/L ) and/or SAA &gt; 10 mg/L ( Normal SAA range &lt; or= 10 mg/L ) time first canakinumab treatment . 1 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/mL ) . 2 . Women childbearing potential , defined premenarche female age 8 year woman physiologically capable become pregnant , UNLESS woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean use highly effective method birth control ( i.e . one result less 1 % per year failure rate use consistently correctly , implant , injectables , combine oral contraceptive , intrauterine device [ IUDs ] ; periodic abstinence [ e.g . calendar , ovulation , symptothermal , postovulation method ] acceptable ) total abstinence discretion investigator case age , career , lifestyle , sexual orientation patient ensure compliance . Women childbearing potential willing use reliable contraception throughout study 3 month study drug discontinuation . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) six month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL surgical bilateral oophorectomy ( without hysterectomy ) least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . 3 . History immunocompromised , include positive HIV screening ( ELISA Western blot ) test result . 4 . Positive QuantiFERON ( QFTTB G InTube ) test positive Purified Protein Derivative ( PPD ) test ( &gt; or= 5 mm induration ) screening within 2 month prior screen visit , accord national guideline . Patients positive PPD test ( &gt; or= 5 mm induration ) screening may enrol either negative chest xray negative QuantiFERON test . 5 . Live vaccination within 3 month prior start trial , trial , 3 month follow last dose . 6 . History significant medical condition , Investigator 's opinion would exclude patient participate trial . 7 . History recurrent and/or evidence active bacterial , fungal , viral infection ( ) . 8 . Use prohibit therapy , investigational biologics within 8 week prior Baseline visit , investigational drug , investigational biologic treatment , within 30 day ( 3 month investigational monoclonal antibody ) 5 halflives prior Baseline visit , whichever longer 9 . History known hypersensitivity canakinumab . 10 . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastases Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>TNF-receptor associate periodic syndrome</keyword>
	<keyword>fever</keyword>
	<keyword>rash</keyword>
	<keyword>musculoskeletal abdominal pain</keyword>
	<keyword>periorbital edema</keyword>
	<keyword>TNFR1</keyword>
</DOC>